Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Hematological Oncologists in Private Practice (US)(?)

Council Members in this Study Group: 79

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Sujith Kalmadi
Staff Physician
Ironwood Cancer & Research Center

Sujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine at the Cleveland Clinic, Ohio. He has interest...

Taral Patel, MD, Oncologist, Mid Ohio Oncology Hematology Inc.Taral Patel, MD
Oncologist
Mid Ohio Oncology Hematology Inc.

Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...

Brian Abbott, MD, Medical Director of Hematology, Big Sky OncologyBrian Abbott, MD
Medical Director of Hematology
Big Sky Oncology

Brian Abbott, MD, is the Medical Director of Hematology at Big Sky Oncology and Sletten Cancer Institute in Great Falls, Montana. His specialties include acute and chronic leukemias (AML, ALL, CML, CLL), all forms of lymphomas including Non-Hodgkin’s and Hodgkin's Lymphoma, myelomas, bone and marrow...

Haitham Al-Okk, MD, Assistant Clinical Professor - Hematology-Oncology, Mahr Cancer CenterHaitham Al-Okk, MD
Assistant Clinical Professor - Hematology-Oncology
Mahr Cancer Center

Haitham Al-Okk, MD, is a Specialist in Hematology-Oncology at Graves-Gilbert Cancer Clinic, a multi-specialty medical group in Kentucky. Dr. Al-Okk is board certified in Internal Medicine and Medical Oncology, and fellowship trained in Hematology-Oncology. He specializes in lung, breast, and colorectal...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
By Brian Abbott, MD, Medical Director of Hematology, Big Sky Oncology

The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.

By Brian Abbott, MD, Medical Director of Hematology, Big Sky Oncology

National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?

By Brian Abbott, MD, Medical Director of Hematology, Big Sky Oncology
Analysis of: Loss of Doctors Leaves Patients Waiting | www.redorbit.com

The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.

February 19, 2008
Avastin In Breast cancer
By Taral Patel, MD, Oncologist, Mid Ohio Oncology Hematology Inc.

New data with low and high dose of Avastin with Taxoter

By Taral Patel, MD, Oncologist, Mid Ohio Oncology Hematology Inc.

esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients'...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Owner
  • Partner
  • Physician - Director
  • Medical Director

GLG's 850+ Clients Include:

Fortune 500®  companies
40 of the leading 50  global mutual funds
15 of the leading 20  global banks
8 of the leading 10  global private equity firms
5 of the top 10  AmLaw firms

Analytics


Generated at 2009-01-08T19:00:17.880